Efficacy of Sublingual Versus Subcutaneous Allergen Immunotherapy in Patients With Bronchial Asthma

• Status: Completed
• Trial end date: 2023-03-10
• Target enrollment: 0
• Participant gender: All

Summary

Asthma is characterized by airway inflammation and is manifested by acute episodes of obstruction related to loss of control of airway inflammation mostly in response to a viral respiratory tract infection .The significance of eosinophilic inflammation in asthma is well established.

Late clinical reactions in asthma are associated with increase of immunoglobulin E (IgE) in serum. Serum IgE can be used as a measure of allergen provocation causing increased eosinophil activity. Serum IgE can be used to assess the exposure to environmental allergens, or decreasing presence of allergen in the environment and the need for increase or reduction of therapy.

Allergen immunotherapy is defined as the repeated administration of specific allergens to patients with IgE-mediated conditions for the purpose of providing protection against the allergic symptoms and inflammatory reactions associated with natural exposure to these allergens.

The aim of this work is to evaluate the effect of sublingual versus subcutaneous allergen immunotherapy as regard clinical response, serum IgE and sputum eosinophils

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Mansoura University Hospital
• Treatments: Immunologic Factors

Criteria

Inclusion Criteria:

• New cases of allergic asthma indicated for immunotherapy (partially controlled by medical treatment with frequent exacerbations)

• Age >18 years

Exclusion Criteria:

• Pregnancy

• Co morbidity such as diabetes, hypertension, ischemic heart, malignancy

• Other causes of the increase in eosinophil as: parasitic infestation

• Acute exacerbation of BA

• Smoker

• Severe persistent asthma